Related references
Note: Only part of the references are listed.VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer
Liju Zong et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
VISTA: Coming of age as a multi-lineage immune checkpoint
M. A. ElTanbouly et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
FOXD3 Regulates VISTA Expression in Melanoma
Sheera R. Rosenbaum et al.
CELL REPORTS (2020)
TISIDB: an integrated repository portal for tumor-immune system interactions
Beibei Ru et al.
BIOINFORMATICS (2019)
The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma
Heike Loeser et al.
ONCOIMMUNOLOGY (2019)
843 Immune checkpoint molecule PD-1H/VISTA expression correlates with melanoma survival
M.D. Vesely et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis
Zefang Tang et al.
NUCLEIC ACIDS RESEARCH (2019)
Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy
Shanjuan Hong et al.
PROTEIN & CELL (2019)
Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression
Wenwen Xu et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer
Apostolos Zaravinos et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins
Rui Gou et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
VISTA expressed in tumour cells regulates T cell function
Kumuluzi Mulati et al.
BRITISH JOURNAL OF CANCER (2019)
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
Jorge Blando et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity
Mohamed A. ElTanbouly et al.
SEMINARS IN IMMUNOLOGY (2019)
VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma
Ming Zhang et al.
BMC CANCER (2018)
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival
Lawrence F. Kuklinski et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
SnapShot: TCGA-Analyzed Tumors
Amy Blum et al.
CELL (2018)
Immune cell landscape in therapy-naive squamous cell and adenocarcinomas of the lung
Luka Brcic et al.
VIRCHOWS ARCHIV (2018)
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
Liru Wang et al.
ONCOIMMUNOLOGY (2018)
Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
Shan Xie et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
VISTA expression by microglia decreases during inflammation and is differentially regulated in CNS diseases
Malte Borggrewe et al.
GLIA (2018)
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
[Anonymous]
NATURE REVIEWS DRUG DISCOVERY (2018)
VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy
Juan-Manuel Hernandez-Martinez et al.
JOURNAL OF THORACIC DISEASE (2018)
Immunotherapy: a glimmer of hope for metastatic prostate cancer
Vishal Jindal
CHINESE CLINICAL ONCOLOGY (2018)
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer
Franz Villarroel-Espindola et al.
CLINICAL CANCER RESEARCH (2018)
New checkpoints in cancer immunotherapy
Ling Ni et al.
IMMUNOLOGICAL REVIEWS (2017)
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
Hojabr Kakavand et al.
MODERN PATHOLOGY (2017)
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao et al.
NATURE MEDICINE (2017)
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Zefang Tang et al.
NUCLEIC ACIDS RESEARCH (2017)
The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
Christine Boeger et al.
ONCOIMMUNOLOGY (2017)
Translating Cancer Genomes and Transcriptomes for Precision Oncology
Sameek Roychowdhury et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma
Yuta Kondo et al.
ORAL ONCOLOGY (2016)
Enhanced VISTA Expression in a Subset of Patients with Acute Myeloid Leukemia
Adam Lamble et al.
BLOOD (2016)
Mechanistic Assessment of PD-1H Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens
Dallas B. Flies et al.
JOURNAL OF IMMUNOLOGY (2015)
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
Jun Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53
Kyoung Wan Yoon et al.
SCIENCE (2015)
Expression of the Novel Costimulatory Molecule B7-H5 in Pancreatic Cancer
Joshua T. Byers et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
VISTA Is an Immune Checkpoint Molecule for Human T Cells
J. Louise Lines et al.
CANCER RESEARCH (2014)
VISTA Regulates the Development of Protective Antitumor Immunity
Isabelle Le Mercier et al.
CANCER RESEARCH (2014)
Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell-mediated immunity
Dallas B. Flies et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Characterization of Programmed Death-1 Homologue-1 (PD-1H) Expression and Function in Normal and HIV Infected Individuals
Preeti Bharaj et al.
PLOS ONE (2014)
VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy
J. Louise Lines et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Cutting Edge: Hypoxia-Induced Nanog Favors the Intratumoral Infiltration of Regulatory T Cells and Macrophages via Direct Regulation of TGF- β1
Meriem Hasmim et al.
JOURNAL OF IMMUNOLOGY (2013)
The Cancer Genome Atlas Pan-Cancer analysis project
John N. Weinstein et al.
NATURE GENETICS (2013)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Li Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models
Dallas B. Flies et al.
JOURNAL OF IMMUNOLOGY (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Hypoxia in cancer: significance and impact on clinical outcome
Peter Vaupel et al.
CANCER AND METASTASIS REVIEWS (2007)
Share Paper
